Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 27.49
XPH's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 27.49 )
Ranked among companies with meaningful PE Ratio only.
XPH' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 28.04
Current: 27.49
0
28.04
PE Ratio without NRI 27.49
XPH's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 27.49 )
Ranked among companies with meaningful PE Ratio without NRI only.
XPH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 28.04
Current: 27.49
0
28.04
PB Ratio 2.68
XPH's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 2.68 )
Ranked among companies with meaningful PB Ratio only.
XPH' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.76
Current: 2.68
0
2.76

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.60
XPH's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.60 )
Ranked among companies with meaningful Dividend Yield % only.
XPH' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.6
Current: 0.6
0
0.6
5-Year Yield-on-Cost % 0.60
XPH's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XPH: 0.60 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
XPH' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.6
Current: 0.6
0
0.6

More Statistics

Short Percentage of Float0.00%
52-Week Range $36.67 - 47.65
Shares Outstanding (Mil)10,500,270.00
» More Articles for XPH

Headlines

Articles On GuruFocus.com
Charlie Tian's Interview on The Next Level Show Jun 28 2017 
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 

More From Other Websites
Why did these generic drugs’ prices jump as much as 85%? Jun 27 2017
Drug stocks surge on report that President Trump plans to ease industry regulations Jun 21 2017
Key Updates on Eli Lilly’s Jardiance Jun 20 2017
Valeant's stock surges after largest shareholder John Paulson elected to board Jun 19 2017
Why Pfizer’s Products Lost Market Share in 1Q17 Jun 08 2017
Performance of Eli Lilly’s New Products Portfolio in 1Q17 Jun 02 2017
Changes in Johnson & Johnson’s Revenue in 1Q17 May 30 2017
Merck’s Immunology and Cardiovascular Franchise in 1Q17 May 25 2017
What Happened to Bristol-Myers Squibb’s Opdivo in 1Q17? May 19 2017
Behind Allergan’s US Specialized Therapeutics Segment in 1Q17 May 10 2017
Valeant's stock soars after profit beats expectations May 09 2017
ETF Flopper: Biotechnology and Pharmaceuticals Feel the Pain May 08 2017
Mallinckrodt's stock jumps after profit and sales beat May 08 2017
Eli Lilly’s 1Q17 Earnings: Cialis and Other Cardiovascular Products May 02 2017
Eli Lilly’s Business Segments and Their Performance in 1Q17 Apr 28 2017
A Look at Bristol-Myers Squibb’s Oncology Segment in 1Q17 Apr 26 2017
Johnson & Johnson’s Consumer Segment’s 1Q17 Earnings Apr 21 2017
Analyst Estimates for Eli Lilly’s 1Q17 Earnings Apr 20 2017
Analysts’ Ratings for Johnson & Johnson in 1Q17 Apr 14 2017
The Hybrid US Healthcare System: An Overview Apr 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK